Summary
Candidaemia is a potentially fatal infection with varied distribution of Candida species and their antifungal susceptibility profiles. The recent emergence of Candida auris in invasive candidiasis is a cause for concern. This study describes the profile of candidaemia at an Indian tertiary care hospital and reports the emergence of C. auris.
All patients diagnosed with candidaemia between 2012 and 2017 were studied. The isolates were identified using conventional methods, VITEK 2 and MALDI-TOF MS.
The isolates not identified by MALDI-TOF were sequenced. Antifungal susceptibility testing was done by the CLSI broth microdilution method and VITEK 2. A total of 114 isolates of Candida species were analysed. Candida tropicalis (39.4%) was the most common species, followed by C. auris (17.5%), C. albicans (14%) and C. parapsilosis (11.4%) . Notably, Diutina mesorugosa isolates (n = 10) were not identified by MALDI-TOF and were confirmed by sequencing. Furthermore, 45% (n = 9) C. auris strains exhibited low MICs of FLU (0.05-4 μg/mL) and the remaining 55% (n = 11) isolates had high MICs ≥ 64 μg/mL. Also, D. mesorugosa exhibited high MICs of FLU (32 μg/ mL) in 2 isolates. A high rate of errors in antifungal susceptibility was noted with the VITEK 2 as compared to the CLSI method. Candida auris was the second most prevalent species causing candidaemia warranting infection control practices to be strengthened to prevent its spread.
K E Y W O R D S
antifungal susceptibility testing, Candida auris, candidaemia, India, MALDI-TOF MS, VITEK 2 Accurate identification of Candida species from invasive candidiasis/BSIs is important in order to initiate appropriate and timely antifungal treatment. Also, antifungal susceptibility testing using a reference method is essential to facilitate accurate treatment of these life-threatening infections. 17, 18 In this study, we report the profile of Candida isolates from cases of candidaemia at a tertiary care hospital and emphasise that many of the C. auris cases and other rare yeast species from BSIs may go unidentified if appropriate methods are not used for identification.
| MATERIALANDME THODS

| Yeastisolatesandtheirphenotypic identification
The study was conducted at a 165-bedded level-1 trauma centre 
| IdentificationbyMALDI-TOFMS
All the isolates were subcultured on Sabouraud dextrose agar (SDA) for 24 hours at 35°C and were identified using the ethanolformic acid extraction method according to the manufacturer's protocol. The spectra were generated and analysed using the Flex 
| DNAsequencingandidentification
Genomic DNA of the isolates was extracted as described by Xu et al. 20 The extracted DNA was subjected to PCR amplification. The PCR was performed to amplify ITS and D1/D2 regions with established primers ITS1 (5′-TCC GTA GGT GAA CCT GCG G-3′) and ITS4
(5′-TCC TCC GCT TAT TGA TAT GC-3′) 21 ; NL1 (5′-GCA TAT CAA TAA GCG GAG GAA AAG-3′), NL4 (5′-GGT CCG TGT TTC AAG ACG G-3′). 22 at 52°C and 56°C. respectively, for 1 minute, and extension at 72°C
for 2 minutes in a thermal cycler.
The amplified products of all the genes were purified (Wizard SV Gel and PCR Clean-up System, Promega) and sequenced. 
| Antifungalsusceptibilitytesting
| CLSIbrothmicrodilutionmethod
In vitro antifungal susceptibility testing (AFST) of all the isolates was carried out using the CLSI broth microdilution method, following M27-A3/S4. 23 The antifungals tested were itraconazole 
| VITEK2method
AFST was also performed by the VITEK 2 method. Each sterile inoculum was prepared in a sterile polystyrene tube equal to 2.0
McFarland from a 24-hour old culture. An AST-YS08 card was inserted into a cassette, to be placed in the VITEK 2 system. The antifungals A comparison between the AFST results of the VITEK 2 and CLSI broth microdilution methods was done and categorical errors were determined. A susceptible result report by the CLSI reference method and resistant report by the VITEK 2 were taken as a major error (ME), whereas a resistant result by the CLSI and susceptible report by the VITEK 2 were taken as a very major error (VME).
Categorical errors were defined as minor if susceptible dose dependent/intermediate was noted by one method and either sensitive or resistant by other method.
| RE SULTS
| Isolateidentification
Of 114 Candida species, 39.4% (n = 45) were identified as C. 
| ComparisonofisolatesidentifiedbyVITEK 2andMALDI-TOFMS
The VITEK 2 yielded correct identification of 65% (n = 74) of the isolates, which included C. tropicalis, C. albicans, C. parapsilosis, and Interestingly C. utilis and C. lusitanae were identified as Candida spp.
by the VITEK 2 (Table 1) . Furthermore, among 13 C. parapsilosis isolates identified in the present study, 61.5% (n = 8) had FLU MIC above ECVs (MICs ≥1 μg/mL).
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These included 6 isolates that exhibited MICs 4-16 μg/mL and 2 isolates with MIC of 1 μg/mL against FLU. Among these FLU non-wildtype (non-WT) isolates, 3 had high MICs for VRC (ECVs ≥0.03 μg/mL) and a single isolate was multiazole resistant (FLU 8 μg/mL, ITC 0.5 μg/mL, VRC 0.125 μg/mL and PSC 0.25 μg/mL).
| AFSTbyVITEK2
We observed that for C. albicans there was complete concordance of results for FC and VRC by the CLSI and the VITEK 2. However, ME was noted in the VITEK AFST for CAS and MFG (1 isolate each);
for AMB, 1 isolate each gave a ME and minor error, and 2 isolates of C. albicans gave ME (12.5%) for FLU. In contrast, in C. auris (n = 20), ME were noted by the VITEK for AMB in 85% (n = 17) of isolates, whereas for FLU 15% (n = 3) of isolates had VME, 10% (n = 2) had ME and 40% (n = 8) isolates demonstrated minor error (Table 3 ). All other antifungals showed complete concordance. For C. tropicalis (n = 45), 4 VME (8.8%) and 30 (66.6%) minor errors were reported by the VITEK for CAS and one ME (2%) was reported for FLU (Table 3) .
Also, ME and minor error for 1 isolate, each (2.22%) of C. tropicalis,
were noted for FC. D. mesorugosa and C. parapsilosis had high rate of resistance to FLU (60% and 54%, respectively) and AMB (10% and 23%, respectively).
| D ISCUSS I ON
We report C. auris as the second most important species causing candidaemia in a tertiary care trauma centre in Delhi, India. Furthermore, we report very high prevalence of C. auris that is 17.5% causing BSIs.
Interestingly, D. mesorugosa, a rare aetiological agent of human infection, was observed as an agent of candidaemia in 8.7% cases in the present series. It was noted that C. auris and D. mesorugosa isolated in this study were evenly distributed over the 5-year time frame suggesting that both these yeast are not agents of episodic/outbreaks but probably have ongoing transmission in our settings. As reported previously all C. auris isolates in the present study were misidentified by the VITEK 2 software version 7.1. 13 Of the 20 isolates of C. auris, 75% were identified as C. haemulonii by the VITEK 2 and interestingly the remaining isolates were misidentified as many other species. Candida auris was first reported from Japan in 2009 from the external ear canal of a patient. 27 In India, it has been reported to account for 5.2% of candidaemia in ICU patients. 28, 29 However, in the present study, C. auris accounted for 17.5% of candidaemia cases in a tertiary care trauma centre in Delhi, which caters to patients all over India emphasising that C. auris is a looming threat in Indian hospitals.
According to estimates, the incidence of candidaemia has increased fivefold globally in the last 10 years, with the developing countries recording a much higher rate of candidaemia as compared to developed countries. 30 Antifungal resistance among NAC species is on the rise, and is an emerging threat to patient management and clinical success. Most worrying in our study was the low rate of susceptibility of C. auris to FLU (55%) and VRC (35%), two of the most commonly used "empiric" antifungals in Indian healthcare in cases of undiagnosed fever/sepsis when antibacterials alone prove ineffective. 33 Most clinical microbiology laboratories depend on automated methods for AFST, since the CLSI-recommended broth microdilution method is labour-intensive. However, we found in our study that a high proportion of strains across different species of Candida displayed ME/VME in AFST results with the VITEK 2.
These discrepant results would ultimately effect selection of appropriate antifungals. A ME in detection would prompt clinicians to unnecessarily use a higher generation/reserved antifungal for treatment. On the other hand, a VME could be a potentially fatal report. Therefore, laboratories need to validate their systems with the reference method and give a guarded report if automated methods are being used.
Finally, evidence suggests that C. auris has a propensity to spread rapidly within and between health care set-ups. In the current scenario of its high prevalence and high rate of resistance, strict infection control protocols are required to prevent the transmission of C. auris in the hospitals. The study also highlights that in the absence of accurate species identification the clinicians are misinformed and may fail to switch treatment to C. auris-specific treatments. 
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